NLS Pharmaceutics AG (NLSP)
Oct 30, 2025 - NLSP was delisted (reason: merged into NCEL)
0.7620
+0.0220 (2.97%)
Inactive · Last trade price on Oct 30, 2025
NLS Pharmaceutics AG Stock Forecast
Stock Price Forecast
There have not been any analyst price target forecasts for NLS Pharmaceutics AG in the last 12 months.
Price Target: n/a
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for NLS Pharmaceutics AG.
Recommendation Trends
| Rating | Apr '23 | May '23 | Jun '23 | Jul '23 | Aug '23 | Sep '23 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Sep 14, 2023 |
| Maxim Group | Maxim Group | Hold → Strong Buy Upgrades $160 | Hold → Strong Buy | Upgrades | $160 | +20,897.38% | Dec 8, 2022 |
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 8, 2022 |
| Laidlaw & Co. | Laidlaw & Co. | Strong Buy Initiates $240 | Strong Buy | Initiates | $240 | +31,396.06% | Sep 6, 2022 |
| Brookline Capital | Brookline Capital | Strong Buy Initiates $480 | Strong Buy | Initiates | $480 | +62,892.13% | Mar 12, 2021 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.46
from -2.63
EPS Next Year
n/a
from -0.46
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 |
|---|---|
| High | n/a |
| Avg | n/a |
| Low | n/a |
Revenue Growth
| Revenue Growth | 2025 |
|---|---|
| High | - |
| Avg | - |
| Low | - |
EPS Forecast
| EPS | 2025 |
|---|---|
| High | -0.47 |
| Avg | -0.46 |
| Low | -0.44 |
EPS Growth
| EPS Growth | 2025 |
|---|---|
| High | - |
| Avg | - |
| Low | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.